Pierre Fabre Pharma GmbH

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colon carcinoma, colonic disorder, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, neoplasm, rectal disorder	Recruiting	Phase 2	2025-02-12	NCT06640166
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Recruiting	Not stated	2022-09-29	NCT04673955
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm	Recruiting	Not stated	2021-01-19	NCT04045691

Clinical trials